8/14/2019 hp press release 11 sep 07

1/3

News release

Editorial co ntac ts:

Elizabe th Arc hiba ld, HP

+1 650 857 4296

elizab eth.archiba ld@hp.c

om

John Mc Guinness

Murray Consultant s for

Crospon

+353 1 498 0361

jmcguinness@murrayconsult

.ie

HP Med ia Hotline

+1 866 266 7272pr@hp.com

www.hp.com/go/newsro

om

Hewlett-Packard

Company

3000 Hano ve r Stree t

Palo Alto, CA 94304

www.hp.com

Crospon Lic enses HP Tec hno logy to Crea teInd ustry-first Skin Pa tc h for Smart Drug Delive ryFusion o f high-tech and b iote c h imp rove s sa fety, effic ac y andea se-of-use for pa tients

PALO ALTO, Ca lif., Sep t. 11, 2007 HP and Crospon , a med ica l de vice

de velop er based in Ga lwa y, Ireland , tod ay a nnounced they have e ntered a

lic ensing ag ree me nt for a d rug d elivery platform tha t ena b les pa inless,

c ontrolled relea se o f one o r mo re d rugs in a single pa tc h ap p lied to the skin.

Under the agreeme nt, HP will lic ense its intellec tua l prop erty to Crospon in

return for roya lty payme nts. Crospon w ill c om me rc ialize the p a tc h, whic h wa s

invented by HP Labs, the c om pany s c entral resea rc h fac ility, and m ake it

availab le to pha rma c eutica l c om pa nies to use in various therap eutic a rea s.

Crospon, which rec ently announc ed the fina liza tion of 2.3 million in seed

financ ing, will manufac ture the skin p atc h a nd ma nag e a ll marketing, sa les and

supp ort of the tec hnology.

The p a tc h d elivers me d ica tion intraderma lly just b elow the surfac e o f the skin

and e nab les p rec ise c ont rol of do sage timing, ac c ess to d osage history,

patient a c tivation m ec hanisms and inherent safety protoc ols for preventing

adverse d rug interac tions.

Transderma l pa tc hes (which rely on a bsorption throug h the skin) for nico tine

delivery have be c om e a ma instay for smo king c essation p rog rams; however,

they have no t been a w idely effec tive delivery me c hanism for ma ny drugs

bec ause the skin a c ts as a na tura l ba rrier.

The HP-develop ed skin p a tc h uses mic rone ed les tha t b arely pe netrate the skin;

this rad ic ally red uces d isc om fort c om pa red to trad itiona l hypode rmic need les

and e nab les the tec hnique to b e used with a much wider variety of drugs and

b iop harmac eutica ls. The m ic ronee dles allow med ic ation to quickly enter the

b loo dstrea m, resulting in the po tentia l delive ry of lowe r and mo re p rec ise

dosages.

HP initially de velop ed the d rug d elivery tec hnolog y as a w ay to rep urpose its

inkjet tec hnolog y for use in new ma rkets. The tec hno log y in the skin p a tc h is

similar to that employed in HPs patented process for its inkjet cartridges.

This industry-first skin p a tc h invented by HP a llow s Crospon to offe r a sup erior

d rug delivery platfo rm for doc tors and pa tients, said John O Dea, c hief

exec utive offic er, Crospon. We loo k forwa rd to wo rking w ith our

8/14/2019 hp press release 11 sep 07

2/3

pharma c eutic a l c ustom ers to b ring this b rea kthroug h solution to the market.

The agreement betw een HP and Crospon resulted in p art from HPs relationship

with Enterprise Ireland , an Irish g ove rnme nt a genc y ta sked with supporting and

grow ing ind igenous business in Ireland . Throug h Ente rprise Ireland , com panies

c an license the intellec tua l p rop erty of HP and a c c ess the c om panys business

and tec hnolog y mentoring.

We enc ourage c om pa nies like Crospo n to ap p ly HPs intellec tual property in

innova tive w ays to he lp mo re p eople b enefit from these importanttechnologies, said Joe Beyers, vice president, Intellectual Property Licensing,

HP. By lic ensing c ore intellec tua l property in the rma l inkjet tec hno log y for use

in a d rug d elivery produc t, HP b rea thes new life into its ma ture tec hnolog y while

c ap italizing o n the b oom ing he a lthc are a nd life sc ienc es ma rket.

HP enc ourag es other organiza tions wo rldwide to leve rage its va st resea rc h and

develop me nt netw ork and po rtfolio of ne arly 30,000 pa tents to bring new

technologies to market through intellectual property licensing agreements.

These a greem ents a lso ena b le HP to g enera te a return on its R&D investment

through licensing fees and roya lties. More informa tion on HP s intellec tua l

p rop erty licensing p rog ram is ava ilab le a twww.hp.com/hpinfo/abouthp/iplicensing/.

About Crospo n

Crospo n, formed in 2006, is a me dica l device c ompany foc used on the

mo nitoring and trea tment of d iab etes and ga stroesop hag ea l reflux disorder

(GERD). Crospon rec ently announc ed the c losure of a 2.3 million seed round

of financ ing, which inc luded investme nt b y Enterprise Ireland and The Western

Development Commission (www.crospon.com). Com pa ny founder and Chief

Exec utive O ffic er John O Dea , previously c o-founded Ca rad yne, a Galwa y,

Ireland-based respiratory products company that was acquired by Respironics

Inc . in 2004.

About HP

HP foc uses on simp lifying tec hno logy experienc es for a ll of its c ustomers from

individua l co nsumers to the largest b usinesses. With a portfo lio tha t spans

p rinting , pe rsona l com puting , softwa re, services and IT infrastruc ture, HP is

amo ng the world s la rge st IT c om panies, with reve nue tota ling $100.5 billion for

the four fisc a l qua rters ended July 31, 2007. More informa tion a bout HP (NYSE:

HPQ) is ava ilab le a t www.hp.com.

Note to e d itors: More news from HP, inc lud ing links to RSS feed s, is ava ilab le a twww.hp.com/hpinfo/newsroom/.

This news relea se c ont ains forwa rd-looking stateme nts that invo lve risks, unc erta inties an d a ssump tions. If suc h risks or

unc ertainties materialize or suc h a ssump tions prove inc orrect, the results of HP and its c onsolidate d subsidiaries could differma terially from tho se e xpressed or implied b y suc h forwa rd-looking state ment s and assump tions. All state ment s othe r thanstateme nts of historica l fact are statem ents that c ould b e d eeme d forward-looking stateme nts, including b ut not limited tostatements of the plans, strategies and objectives of management for future operations; any statements concerningexpec ted developm ent, performanc e or ma rket share relating to p roducts and services; anticipated ope rational andfinanc ial results; any state ment s of expe c tation o r belief; and any statem ents of assump tions unde rlying any o f the foreg oing.Risks, unce rtainties and assump tions include the e xecution and pe rforma nc e o f c ontrac ts by HP and its custom ers, supp liersand pa rtners; the a c hieveme nt of e xpec ted results; and othe r risks that are d escribe d in HPs Quarterly Rep ort on Form 10-Qfor the fisca l qua rter end ed Ap ril 30, 2007 and HPs other filings with the Sec urities and Excha nge Com mission, including b utnot limited to HPs Annual Rep ort on Form 10-K for the fisc al yea r ende d O c t. 31, 2006. HP assumes no o bligation a nd do es notintend to upd ate these forward-looking statem ents.

http://www.hp.com/hpinfo/abouthp/iplicensing/http://../elp/Local%20Settings/Temporary%20Internet%20Files/OLK2F/www.crospon.comhttp://www.hp.com/http://www.hp.com/hpinfo/newsroom/http://www.hp.com/hpinfo/newsroom/http://www.hp.com/http://../elp/Local%20Settings/Temporary%20Internet%20Files/OLK2F/www.crospon.comhttp://www.hp.com/hpinfo/abouthp/iplicensing/

8/14/2019 hp press release 11 sep 07

3/3

2007 Hewlett-Pac kard Deve lopme nt Com pa ny, L.P. The informa tion co ntained herein is subjec t to c han ge w ithoutnotic e. The o nly wa rranties for HP produc ts and services are set forth in the express warranty state ment sac co mpa nying such p roducts and service s. Nothing he rein should b e c onstrued as constituting an ad ditionalwa rranty. HP shall not be liab le for tec hnica l or ed itorial errors or om issions c onta ined herein.

09/2007